What's Happening?
Ionis Pharmaceuticals has announced the completion of enrollment for the pivotal cohort of its Phase 3 REVEAL study, which is evaluating obudanersen, an investigational RNA-targeted medicine for Angelman syndrome (AS). This rare neurodevelopmental disorder
is characterized by significant impairments in communication, physical function, and cognition. The pivotal cohort includes 136 participants aged 2 to under 18 years with a confirmed clinical diagnosis of AS. The study aims to assess the efficacy of obudanersen in improving expressive communication, a primary endpoint, along with secondary endpoints such as overall disease severity and motor functioning. The adult cohort, comprising participants aged 18 to 50, is expected to complete enrollment by the third quarter of 2026. Topline data from the study is anticipated in the second half of 2027.
Why It's Important?
The completion of enrollment in this study marks a significant step towards potentially providing a disease-modifying treatment for Angelman syndrome, a condition with no approved therapies. The study's design, which includes a broad range of participants, reflects the real-world diversity of the condition and aims to address the most meaningful symptoms for caregivers. Success in this trial could lead to a breakthrough in treating AS, offering hope to patients and families affected by this debilitating disorder. Additionally, the study's outcomes could influence future research and development in the field of rare neurological diseases.
What's Next?
Ionis plans to advance obudanersen into the Phase 3 CHAMPION study, targeting individuals with AS who have uniparental disomy or imprinting defect genotypes. This study is expected to begin before the end of 2026. The results from the REVEAL study will be crucial in determining the next steps for regulatory approval and potential commercialization of obudanersen. Stakeholders, including patients, healthcare providers, and regulatory bodies, will be closely monitoring the study's progress and outcomes.
